Crinetics Pharmaceuticals (CRNX)
Crinetics Pharmaceuticals on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
6.8M
Short interest
settlement 2026-08-31
2.4
Days to cover
-0.7 days vs prior
53.2%
Short share of volume
2026-08-31
72
Fails to deliver
settlement 2026-09-02
Thu 5 Nov
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-09-02.
Short interest
FINRA, twice a month. The newest 24 settlements in the table, 48 in the chart. JSONAs of 31 August 2026, short interest in CRNX is 6,847,147 shares, up 980,722 shares over the last month. Over the last 48 readings it ranged from 5,866,425 shares (31 July 2026) to 16,056,257 shares (31 March 2026). The latest reading sits at the bottom of that range. At the reported average volume of 2.9M shares a day that is 2.4 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/crnx" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-08-31 | 6,847,147 | +3.9% | 2,870,656 | 2.39 |
| 2026-08-14 | 6,588,676 | +12.3% | 2,103,671 | 3.13 |
| 2026-07-31 | 5,866,425 | -5.6% | 3,297,953 | 1.78 |
| 2026-07-15 | 6,212,042 | -55.1% | 13,437,117 | 1.00 |
| 2026-06-30 | 13,845,220 | +7.7% | 1,507,027 | 9.19 |
| 2026-06-15 | 12,856,719 | +1.7% | 971,484 | 13.23 |
| 2026-05-29 | 12,639,107 | -4.1% | 918,983 | 13.75 |
| 2026-05-15 | 13,177,402 | -7.0% | 1,618,584 | 8.14 |
| 2026-04-30 | 14,170,153 | +10.7% | 1,115,715 | 12.70 |
| 2026-04-15 | 12,795,329 | -20.3% | 1,002,864 | 12.76 |
| 2026-03-31 | 16,056,257 | +4.5% | 1,348,151 | 11.91 |
| 2026-03-13 | 15,363,638 | +8.5% | 1,085,768 | 14.15 |
| 2026-02-27 | 14,158,444 | -2.0% | 786,475 | 18.00 |
| 2026-02-13 | 14,453,914 | +0.9% | 1,127,771 | 12.82 |
| 2026-01-30 | 14,320,938 | -4.7% | 926,477 | 15.46 |
| 2026-01-15 | 15,026,357 | +12.7% | 2,179,105 | 6.90 |
| 2025-12-31 | 13,334,004 | -6.3% | 927,070 | 14.38 |
| 2025-12-15 | 14,227,298 | +2.5% | 1,005,949 | 14.14 |
| 2025-11-28 | 13,873,038 | -12.9% | 1,206,069 | 11.50 |
| 2025-11-14 | 15,921,779 | +17.6% | 1,859,966 | 8.56 |
| 2025-10-31 | 13,537,482 | +8.8% | 1,209,604 | 11.19 |
| 2025-10-15 | 12,440,159 | +0.5% | 1,690,036 | 7.36 |
| 2025-09-30 | 12,384,250 | -16.0% | 2,461,507 | 5.03 |
| 2025-09-15 | 14,750,119 | +5.5% | 1,346,370 | 10.96 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 31 August 2026, the short share of CRNX volume is 53.2%, up 31.7 points over the last five sessions. Over the last 30 readings it ranged from 1.9% (20 August 2026) to 53.2% (31 August 2026). The latest reading sits at the top of that range. The latest reading is 27.5 points above the 30-session average of 25.7%, on 1.3M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-08-31 | 700K | 1.3M | 53.2% | 432 |
| 2026-08-28 | 68K | 189K | 36.0% | 0 |
| 2026-08-27 | 30K | 104K | 29.0% | 0 |
| 2026-08-26 | 59K | 160K | 36.6% | 0 |
| 2026-08-25 | 82K | 651K | 12.6% | 7,779 |
| 2026-08-24 | 66K | 307K | 21.5% | 5 |
| 2026-08-21 | 250K | 594K | 42.1% | 33,573 |
| 2026-08-20 | 161K | 8.4M | 1.9% | 739 |
| 2026-08-19 | 143K | 1.1M | 12.5% | 2,791 |
| 2026-08-18 | 569K | 2.0M | 29.0% | 1,025 |
| 2026-08-17 | 115K | 447K | 25.8% | 1,941 |
| 2026-08-14 | 238K | 1.4M | 17.5% | 3,162 |
| 2026-08-13 | 147K | 416K | 35.4% | 1,451 |
| 2026-08-12 | 105K | 1.8M | 5.9% | 1,006 |
| 2026-08-11 | 61K | 933K | 6.5% | 67 |
| 2026-08-10 | 123K | 1.0M | 12.2% | 1 |
| 2026-08-07 | 357K | 1.1M | 32.3% | 3,575 |
| 2026-08-06 | 421K | 1.2M | 35.1% | 2,551 |
| 2026-08-05 | 442K | 998K | 44.3% | 2,562 |
| 2026-08-04 | 532K | 1.1M | 47.8% | 4,941 |
| 2026-08-03 | 196K | 545K | 36.0% | 12,184 |
| 2026-07-31 | 182K | 598K | 30.4% | 117 |
| 2026-07-30 | 213K | 668K | 31.9% | 2,781 |
| 2026-07-29 | 105K | 779K | 13.5% | 1,081 |
| 2026-07-28 | 135K | 1.3M | 10.6% | 985 |
| 2026-07-27 | 375K | 1.2M | 30.4% | 7,984 |
| 2026-07-24 | 203K | 925K | 21.9% | 174 |
| 2026-07-23 | 639K | 2.1M | 29.8% | 10,125 |
| 2026-07-22 | 281K | 1.6M | 17.6% | 2,253 |
| 2026-07-21 | 179K | 1.4M | 12.3% | 2,033 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 September 2026, the fails-to-deliver balance in CRNX is 72 shares, down 518,211 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (23 March 2026) to 518,283 shares (1 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-09-02 | 72 | $84.95 | $6K |
| 2026-09-01 | 518,283 | $84.95 | $44.0M |
| 2026-08-31 | 3,148 | $84.84 | $267K |
| 2026-08-27 | 78 | $84.84 | $7K |
| 2026-08-25 | 35 | $84.78 | $3K |
| 2026-08-21 | 3 | $84.69 | $254 |
| 2026-08-11 | 18 | $84.15 | $2K |
| 2026-08-03 | 52 | $83.52 | $4K |
| 2026-07-22 | 145 | $83.90 | $12K |
| 2026-07-14 | 292,982 | $83.67 | $24.5M |
| 2026-07-13 | 79 | $83.58 | $7K |
| 2026-07-09 | 3,999 | $83.49 | $334K |
| 2026-07-07 | 73,728 | $42.03 | $3.1M |
| 2026-07-06 | 900 | $42.23 | $38K |
| 2026-06-30 | 9,252 | $36.94 | $342K |
| 2026-06-29 | 399 | $36.70 | $15K |
| 2026-06-23 | 2 | $35.38 | $71 |
| 2026-06-22 | 8,400 | $35.87 | $301K |
| 2026-06-18 | 419 | $35.75 | $15K |
| 2026-06-10 | 21,030 | $34.97 | $735K |
| 2026-06-02 | 1,500 | $34.52 | $52K |
| 2026-05-28 | 251 | $36.79 | $9K |
| 2026-05-21 | 5 | $36.27 | $181 |
| 2026-04-20 | 6,703 | $41.00 | $275K |
| 2026-04-13 | 1,792 | $39.44 | $71K |
| 2026-04-08 | 150 | $38.41 | $6K |
| 2026-04-06 | 24 | $37.23 | $894 |
| 2026-04-02 | 49,064 | $36.57 | $1.8M |
| 2026-03-24 | 255 | $34.71 | $9K |
| 2026-03-23 | 1 | $35.57 | $36 |
Insider trades
SEC Form 4, newest first, 50 of 100 shown. JSONNo open-market insider trades were reported for CRNX in the last 90 days. The most recent filings are listed below. Latest filing: Struthers Richard Scott (President & CEO) on 2026-09-01.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 111K | $85.00 | $9.4M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 111K | $85.00 | $9.4M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 111K | $85.00 | $9.4M | 0 |
| 2026-09-01 | WIERENGA WENDELL | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | WIERENGA WENDELL | Director | Disposition | 116K | $85.00 | $9.9M | 6K |
| 2026-09-01 | Vivaldi Coelho Rogerio | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | Vivaldi Coelho Rogerio | Director | Disposition | 13K | $85.00 | $1.1M | 6K |
| 2026-09-01 | Okey Stephanie | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | Okey Stephanie | Director | Disposition | 6K | $85.00 | $544K | 6K |
| 2026-09-01 | Nichols Weston | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | Nichols Weston | Director | Disposition | 16K | $85.00 | $1.4M | 6K |
| 2026-09-01 | Fust Matthew K | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | Fust Matthew K | Director | Disposition | 23K | $85.00 | $1.9M | 6K |
| 2026-09-01 | Deardorf Caren | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | Deardorf Caren | Director | Disposition | 16K | $85.00 | $1.4M | 6K |
| 2026-09-01 | Kalofonos Isabel | Chief Commercial Officer | Disposition | 34K | $85.00 | $2.9M | 0 |
| 2026-09-01 | Kalofonos Isabel | Chief Commercial Officer | Disposition | 2K | $85.00 | $142K | 34K |
| 2026-09-01 | Schilke Tobin | Chief Financial & Infra. Ofcr. | Disposition | 71K | $85.00 | $6.1M | 0 |
| 2026-09-01 | Schilke Tobin | Chief Financial & Infra. Ofcr. | Disposition | 8K | $85.00 | $676K | 71K |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 177K | $85.00 | $15.0M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 80K | $85.00 | $6.8M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 111K | $85.00 | $9.4M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 100K | $85.00 | $8.5M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 110K | $85.00 | $9.3M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 106K | $85.00 | $9.0M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 137K | $85.00 | $11.6M | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 1K | $85.00 | $85K | 0 |
| 2026-09-01 | Struthers Richard Scott | President & CEO | Disposition | 248K | $85.00 | $21.1M | 177K |
| 2026-09-01 | Betz Stephen F. | Chief Scientific Officer | Disposition | 80K | $85.00 | $6.8M | 0 |
| 2026-09-01 | Betz Stephen F. | Chief Scientific Officer | Disposition | 58K | $85.00 | $5.0M | 80K |
| 2026-09-01 | Bedrosian Camille L | Director | Disposition | 6K | $85.00 | $504K | 0 |
| 2026-09-01 | Bedrosian Camille L | Director | Disposition | 16K | $85.00 | $1.4M | 6K |
| 2026-08-20 | Schilke Tobin | Chief Financial & Infra. Ofcr. | Grant | 471 | $0.00 | $0 | 79K |
| 2026-08-07 | Struthers Richard Scott | President & CEO | Option exercise | 5K | $20.02 | $100K | 425K |
| 2026-08-07 | Struthers Richard Scott | President & CEO | Option exercise | 7K | $15.29 | $100K | 420K |
| 2026-08-07 | Struthers Richard Scott | President & CEO | Option exercise | 4K | $22.61 | $100K | 413K |
| 2026-08-07 | Struthers Richard Scott | President & CEO | Option exercise | 4K | $25.19 | $100K | 409K |
| 2026-07-02 | Vivaldi Coelho Rogerio | Director | Sell | 3K | $40.00 | $120K | 19K |
| 2026-06-18 | Okey Stephanie | Director | Grant | 6K | $0.00 | $0 | 12K |
| 2026-06-18 | WIERENGA WENDELL | Director | Grant | 6K | $0.00 | $0 | 122K |
| 2026-06-18 | Bedrosian Camille L | Director | Grant | 6K | $0.00 | $0 | 22K |
| 2026-06-18 | Vivaldi Coelho Rogerio | Director | Grant | 6K | $0.00 | $0 | 22K |
| 2026-06-18 | Nichols Weston | Director | Grant | 6K | $0.00 | $0 | 22K |
| 2026-06-18 | Fust Matthew K | Director | Grant | 6K | $0.00 | $0 | 29K |
| 2026-06-18 | Deardorf Caren | Director | Grant | 6K | $0.00 | $0 | 22K |
| 2026-06-17 | Okey Stephanie | Director | Sell | 6K | $35.62 | $224K | 7K |
| 2026-06-17 | Okey Stephanie | Director | Sell | 608 | $36.22 | $22K | 6K |
| 2026-05-29 | Struthers Richard Scott | President & CEO | Gift | 111K | $0.00 | $0 | 111K |
| 2026-05-29 | Struthers Richard Scott | President & CEO | Gift | 111K | $0.00 | $0 | 111K |
| 2026-05-29 | Struthers Richard Scott | President & CEO | Gift | 111K | $0.00 | $0 | 1K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON22 Form 144 notices on file for CRNX worth $14.3M at the prices reported; 0 in the last 90 days worth $0. Latest: JEFF KNIGHT filed on 2026-07-02 to sell 47,420 shares ($1.8M) from 2026-07-02.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-07-02 | JEFF KNIGHTOfficer | 47K | $1.8M | 0.045% | 2026-07-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-07-02 | ROGERIO VIVALDI COELHODirector | 6K | $232K | 0.006% | 2026-07-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-06-17 | STEPHANIE OKEYDirector | 7K | $242K | 0.007% | 2026-06-17 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-05-04 | JEFF KNIGHTOfficer | 9K | $370K | 0.009% | 2026-05-04 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-14 | JEFF KNIGHTOfficer | 21K | $808K | 0.020% | 2026-04-14 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-13 | JEFF KNIGHTOfficer | 4K | $175K | 0.004% | 2026-04-13 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-04-08 | JEFF KNIGHTOfficer | 85K | $3.3M | 0.081% | 2026-04-08 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-18 | DANA PIZZUTIOfficer | 25K | $938K | 0.024% | 2026-03-18 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | Jeff KnightOfficer | 25K | $941K | 0.024% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | Richard Scott StruthersDirector, Officer | 45K | $1.7M | 0.043% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-16 | Stephen BetzOfficer | 27K | $994K | 0.025% | 2026-03-16 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-12 | ROGERIO VIVALDI COELHODirector | 5K | $185K | 0.005% | 2026-03-12 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-03 | STEPHANIE S OKEYDirector | 3K | $122K | 0.003% | 2026-03-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-03-02 | Tobin SchilkeOfficer | 7K | $280K | 0.007% | 2026-03-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-02-02 | DANA PIZZUTIOfficer | 10K | $499K | 0.011% | 2026-02-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-05 | ISABEL KALOFONOSOfficer | 3K | $117K | 0.003% | 2026-01-05 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-01-02 | DANA PIZZUTIOfficer | 5K | $233K | 0.005% | 2026-01-02 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-12-01 | DANA PIZZUTIOfficer | 5K | $228K | 0.005% | 2025-12-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-11-03 | DANA PIZZUTIOfficer | 5K | $218K | 0.005% | 2025-11-03 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-10-01 | DANA PIZZUTIOfficer | 5K | $208K | 0.005% | 2025-10-01 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2025-09-26 | Struthers Richard ScottOfficer, Director | 4K | $180K | 0.004% | 2025-09-26 | UBS Financial Services Inc. |
| 2025-09-26 | MATTHEW K FUSTDirector | 16K | $574K | 0.017% | 2025-09-26 | Morgan Stanley Smith Barney LLC Executive Financial Services |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON23 holders report 5% or more of CRNX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Wehrly, Mark C. at 8.5% of the class (8,989,098 shares), filed 2026-08-03 for an event on 2026-06-30.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-13 | 13G/Ano. 5 | Wellington Group Holdings LLPparent holding company | 7.1M | 6.8% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Wellington Investment Advisors Holdings LLPparent holding company | 7.1M | 6.8% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Wellington Management Group LLPparent holding company | 7.1M | 6.8% | 2026-06-30 |
| 2026-08-13 | 13G/Ano. 5 | Wellington Management Company LLPinvestment adviser | 7.1M | 6.4% | 2026-06-30 |
| 2026-08-07 | 13G/Ano. 4 | FMR LLCparent holding company | 1.4M | 1.4% | 2026-07-31 |
| 2026-08-07 | 13G/Ano. 4 | Abigail P. Johnsonindividual | 1.4M | 1.4% | 2026-07-31 |
| 2026-08-03 | 13G/Ano. 2 | Wehrly, Mark C.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital Management, L.L.C.investment adviser, other entity | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Dapice Joshua J.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Dreyfuss, Philip D.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Dunn Hannah E.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Gehani, Varun N.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Giauque, Nicolasparent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Husen, Avner A.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Kim, David T.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Luo Patrick (Cheng)parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Linn, Michael G.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Roberts, Jr., Thomas G.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Saito Edric C.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Short Daniel S.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Spokes, Andrew J. M.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Warren, John R.parent holding company, individual | 9.0M | 8.5% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Partners, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital Institutional Partners, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital Institutional Partners II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital Institutional Partners III, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Four Crossings Institutional Partners V, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital Offshore Investors II, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital (AM) Investors, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Capital F5 Master I, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Healthcare Partners Master, L.P.partnership | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Institutional (GP) V, L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon F5 (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-08-03 | 13G/Ano. 2 | Farallon Healthcare Partners (GP), L.L.C.other entity | 0 | 0.0% | 2026-06-30 |
| 2026-05-15 | 13G/Ano. 3 | DRIEHAUS CAPITAL MANAGEMENT LLCinvestment adviser | 6.4M | 6.1% | 2026-03-31 |
| 2026-05-15 | 13G/Ano. 1 | T. Rowe Price Associates, Inc.investment adviser | 5.4M | 5.1% | 2026-03-31 |
| 2026-04-29 | 13G | Vanguard Capital Managementinvestment adviser | 5.4M | 5.2% | 2026-03-31 |
| 2026-03-26 | 13G/Ano. 5 | The Vanguard Groupinvestment adviser | 0 | 0.0% | 2026-03-13 |
| 2026-02-05 | 13G/Ano. 1 | Patel, Rajiv A.individual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 1 | Fried, Richard Bindividual | 0 | 0.0% | 2025-12-31 |
| 2026-02-05 | 13G/Ano. 1 | Seybold, Williamindividual | 0 | 0.0% | 2025-12-31 |
13F holders
Tracked managers holding CRNX at their latest 13F. JSON4 of the 30 tracked managers held CRNX at their latest 13F, $37.9M in total at quarter-end prices. Fisher Asset Management is the largest at $27.7M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 1 added shares and 2 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Fisher Asset Management | 2026-06-30 | 742K | $27.7M | 0.01% | -21K |
| Citadel Advisors | 2026-06-30 | 138K | $5.2M | 0.00% | -180K |
| Two Sigma Investments | 2026-06-30 | 87K | $3.3M | 0.00% | 0 |
| Point72 Asset Management | 2026-06-30 | 46K | $1.7M | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn Q2 FY 2026 (quarter ended 2026-06-30) Crinetics Pharmaceuticals reported revenue of $25.1M, up 2336.3% from the same quarter a year earlier, and net loss of $120.9M (-1.14 diluted EPS). In FY 2025 it generated -$377.9M of operating cash flow.
- Cash
- $55.5M
- Equity
- $1.19B
- Total assets
- $1.32B
- Shares outstanding
- 106,065,229
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | $25.1M | -$120.9M | -481.1% | -1.14 |
| Q1 FY 2026 | 2026-03-31 | $10.7M | -$127.8M | -1191.0% | -1.23 |
| Q4 FY 2025derived | 2025-12-31 | $6.2M | n/a | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | $143K | -$130.1M | -90972.7% | -1.38 |
| Q2 FY 2025 | 2025-06-30 | $1.0M | -$115.6M | -11216.0% | -1.23 |
| Q1 FY 2025 | 2025-03-31 | $361K | -$96.8M | -26807.2% | -1.04 |
| Q4 FY 2024derived | 2024-12-31 | $0 | n/a | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | $0 | -$76.8M | n/a | -0.96 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $7.7M | -$465.3M | -$377.9M | $5.8M | n/a | n/a |
| FY 2024 | 2024-12-31 | $1.0M | -$298.4M | -$230.2M | $3.8M | n/a | n/a |
| FY 2023 | 2023-12-31 | $4.0M | -$214.5M | -$168.6M | $4.7M | n/a | n/a |
| FY 2022 | 2022-12-31 | $0 | -$163.9M | -$115.2M | $1.7M | n/a | n/a |
| FY 2021 | 2021-12-31 | $0 | -$107.6M | -$88.6M | $436K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-22 from the cover page.
What this page is
Crinetics Pharmaceuticals in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Crinetics Pharmaceuticals (CRNX), SEC CIK 1658247, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-08-31.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-08-31.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-09-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-07-02.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-13.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-03.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-09-01.JSON and CSV
- Company record
- EDGAR filing index for CIK 1658247Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
- UTHRUnited Therapeutics
- CPIXCumberland Pharmaceuticals
- REGNRegeneron Pharmaceuticals
- LLYEli Lilly
- VRTXVertex Pharmaceuticals
- ALNYAlnylam Pharmaceuticals
- CYTKCytokinetics
- BMYBristol Myers Squibb
- PTCTPTC Therapeutics
- INSMInsmed
- MDGLMadrigal Pharmaceuticals
- CORTCorcept Therapeutics
- IONSIonis Pharmaceuticals
- SDGRSchrodinger
- ROIVRoivant Sciences
- JNJJohnson & Johnson
- OPKOpko Health
- ALKSAlkermes
- ABBVAbbVie
- ABTAbbott Laboratories
- KNSAKiniksa Pharmaceuticals International
- BBIOBridgeBio Pharma
- ZTSZoetis
- JAZZJazz Pharmaceuticals
Datasets
Frequently Asked Questions
How much of CRNX is sold short?
6,847,147 shares were held short at the 2026-08-31 settlement, 2.4 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is CRNX's daily short volume?
On 2026-08-31, 699,708 of the 1,315,502 CRNX shares reported to FINRA were sold short, 53.2% of the day's reported volume. Short volume is a flow for one day, not a position.
Does CRNX have fails to deliver?
The SEC's latest file shows 72 CRNX shares failed to deliver at settlement 2026-09-02. Fails are reported per settlement date and published twice a month with a lag.
Are CRNX insiders buying or selling?
No open-market insider trades were reported for CRNX in the last 90 days. The most recent filings are listed below. Latest filing: Struthers Richard Scott (President & CEO) on 2026-09-01.
Have CRNX insiders filed to sell?
22 Form 144 notices on file for CRNX worth $14.3M at the prices reported; 0 in the last 90 days worth $0. Latest: JEFF KNIGHT filed on 2026-07-02 to sell 47,420 shares ($1.8M) from 2026-07-02.
Who owns 5% or more of CRNX?
23 holders report 5% or more of CRNX in their latest filing, all on Schedule 13G (passive). The largest reported stake is Wehrly, Mark C. at 8.5% of the class (8,989,098 shares), filed 2026-08-03 for an event on 2026-06-30.
What did CRNX report last quarter?
In Q2 FY 2026 (quarter ended 2026-06-30) Crinetics Pharmaceuticals reported revenue of $25.1M, up 2336.3% from the same quarter a year earlier, and net loss of $120.9M (-1.14 diluted EPS). In FY 2025 it generated -$377.9M of operating cash flow.
Which tracked 13F managers own CRNX?
4 of the 30 tracked 13F managers held CRNX shares at their latest filing, $37.9M in all. The largest: Ken Fisher's Fisher Asset Management (742K shares, $27.7M), Ken Griffin's Citadel Advisors (138K shares, $5.2M), Two Sigma Investments (87K shares, $3.3M), Steve Cohen's Point72 Asset Management (46K shares, $1.7M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.